G. Walmsley Graham, Director at Akero Therapeutics, Inc. (AKRO), bought 200,000 shares at $16.99 ($3.4M) on 2023-12-01, disclosed to the SEC on 2023-12-05.
Open-market purchase of $3.4M AKRO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.90 | 50,000 | $845K | 24.9% |
| 2 | $16.90 | 50,000 | $845K | 24.9% |
| 3 | $16.99 | 50,000 | $849K | 25.1% |
| 4 | $16.99 | 50,000 | $850K | 25.1% |
| Total | $16.95 avg | 200,000 | $3.4M | 100% |
| Filing → |
| OLMA | SELL | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-17 | $4.7M | — | Filing → |